- Toll Free: +1-800-792-5285
- (UK): +44-845-528-1300
- Int'l: +1-503-894-6022
- Help@alliedmarketresearch.com
Cart
|
LI_183622
|
Pages: 180
|
Jan 2018 | 3333 Views
|
|
|
|
Author(s) :
Pallavi Jaiswal & Mayuri Srivastava
|
Tables: 117
|
Charts: 37
|
Formats*: |
|
The Global Coated Endotracheal Tube Market was valued at $1,629 million in 2016, and is estimated to reach $2,518 million at a CAGR of 6.3% from 2017 to 2023. Endotracheal tubes are medical devices used for intubation into the trachea to maintain an open airway and to administer certain drugs. There are used for mechanical ventilation, thus there is risk for microbial invasion into the airways. Therefore, to prevent or reduce the incidence of hospital acquired infection or ventilator-associated pneumonia (VAP), endotracheal tubes are coated with a drug-releasing coating that releases antimicrobial agents to inhibit bacterial growth and biofilm formation. Coated endotracheal tube includes variety of endotracheal tubes coated with drugs or materials, which offer antimicrobial properties to endotracheal tube. Coatings include heparin, silver, chlorhexidine, rifampicin, and minocycline agents.
Advantages of Coated Endotracheal Tubes
Coated endotracheal tubes are advantageous because coatings have a broad-spectrum antimicrobial activity in vitro, that reduces bacterial adhesion and restricts the biofilm formation on the tube surface. This in turn blocks the occurrence of type of hospital-associated infection called ventilator-associated pneumonia. Ventilator-associated pneumonia (VAP) is a type of infection that mainly occurs in patients with mechanical ventilation and it is caused due to the growth of microorganism on the surface of air management devices, thereby causing illness. According to the infectious diseases society of America/American thoracic society guidelines, 2016, VAP develops 48‐72 hours after endotracheal intubation. Moreover, VAP affects 28% of patients who are on mechanical ventilation. Therefore, VAP is an important source of morbidity and mortality in critically ill patients. The mortality rate attributed to VAP is 27% and as high as 43% when the causative agent is antibiotic resistant.
Hence, it is important to prevent VAP infections by replacing the non-coated endotracheal tubes with coated endotracheal tubes. Endotracheal tubes if coated with antibiotic agents such as drugs and silver, will prevent the growth of microorganisms during ventilation. Therefore, increase in incidence of VAP is projected to upsurge the need of coated endotracheal tubes, thus boosting the market growth.
Market Segmentation
The global coated endotracheal tube market is segmented based on intubation, application, end user, and region. Based on the intubation, the market is bifurcated into orotracheal intubation and nasotracheal intubation. Based on application, the market is categorized into anesthesia, emergency medicine, and others. Based on end user, the market is classified into hospital, clinics, and ambulatory surgical centers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get more information on this report : Request Sample Pages
Segment Review
Orotracheal intubation segment accounted for the largest market share in 2016 and is expected to remain so throughout the forecast period. Orotracheal intubation is a process of passing an endotracheal tube through the mouth to trachea. The tube, which is inserted through mouth is known as orotracheal tube. Orotracheal intubation is less painful and easy to perform. It is mainly used in emergency situations such as cardiac or respiratory arrest, inadequate oxygenation or ventilation, and airway obstruction. Orotracheal intubation is easier to perform, faster and less painful under direct laryngoscopy.
Get more information on this report : Request Sample Pages
Geographic Review
Based on region, the global market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2016, followed by Europe. On the other hand, Asia-Pacific is anticipated to be the fastest-growing regional segment during the analysis period. Asia-Pacific presents lucrative opportunities for players operating in the coated endotracheal tubes market, attributable to its high population base, increase in disposable incomes, and improvement in patient awareness about ventilator associated pneumonia. Asia is a large continent, and is a home to some of the world’s highly populous countries. This region has emerged as an epicenter of cancer, lung injuries, and cardiovascular diseases epidemics.
Get more information on this report : Request Sample Pages
The key players of this market include C.R. Bard, Bactiguard Holding AB, Enox Biopharma Inc., Hospiteknik Healthcare, Innovative Surface Technologies, N8 Medical, LLC, Sharklet Technologies, Inc., Sonoma Pharmaceuticals, Inc., Teleflex Incorporated, and Venner Medical International.
Pipeline Analysis
Pipeline products include coated endotracheal tubes developed by major key players that are still in clinical stages. These products are as follows
Company Name | Product Name | Description |
N8 Medical LLC | CeraShield endotracheal tube | CeraShield endotracheal tube is designed to address a myriad of complications in mechanically-ventilated patients. It prevents or reduce microbial colonization and biofilm growth on the tube surface, thereby reducing length of hospital stay and risk of infection and death. |
Innovative Surface Technologies, Inc. | ISurTec Endotracheal tubes (Clinical phase 1) | ISurTec is developing a drug-releasing superhydrophobic coating for endotracheal tubes prevents or reduce the incidence of ventilator associated pneumonia. |
Sharklet Technologies | Micropatterned Endotracheal Tubes | Micropatterned endotracheal tubes reduce the accumulation of normal airway secretion and improve patient care. |
Key Benefits
The adoption of endotracheal tubes is expected to increase due to rise in various types of chronic diseases such as cardiovascular disorders and diabetes. These tubes provide proper airway management during surgical procedures and prevent airway obstruction.
Upsurge in cases of chronic diseases and increase in prevalence of diabetes make it imperative to use endotracheal tubes during intubation processes or surgeries. Moreover, increase in prevalence of ventilator associated pneumonia, advantages of coated endotracheal tubes with lesser side effects, rise in geriatric population, and surge in affordability in the developing economies are projected to supplement the market growth. However, complications associated with these tubes and dearth of skilled professionals are expected to impede the market growth. Â
The use of coated endotracheal tubes is highest in North America, owing to increased usage of endotracheal intubation and heavy expenditure by the government on healthcare, followed by Europe and Asia-Pacific. In addition, coated endotracheal tubes providers and distributors have focused on expanding their presence in the emerging economies, which is anticipated to drive the market growth.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
